Laigo Bio, a spin-out from UMC Utrecht and Oncode Institute, has secured a €11.5 million investment round led by Kurma Partners to accelerate development of SureTAC™, its proprietary targeted protein-degradation platform.
Laigo Bio emerges from a strong scientific and translational foundation established at UMC Utrecht and Oncode Institute. The core technology was conceived and advanced in the laboratory of Prof. Madelon Maurice (Oncode Investigator, UMC Utrecht), laying the groundwork for company formation.
From the earliest stages, Oncode Institute and UMC Utrecht supported translation through scientific guidance and company-building support. The Oncode Oncology Bridge Fund provided pre-seed financing that helped de-risk the platform and catalyze follow-on investment.
With this new financing, Laigo Bio will deepen its research pipeline initially focused on oncology and build the team for further development. The company also plans expansion into neuro-inflammatory and neurodegenerative disease areas.